MESO - MESOBLAST LTD
15.51
0.010 0.064%
Share volume: 87,771
Last Updated: 04-24-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.21%
PREVIOUS CLOSE
CHG
CHG%
$15.50
0.01
0.00%
Fundamental analysis
3%
Profitability
0%
Dept financing
9%
Liquidity
24%
Performance
0%
Performance
5 Days
-6.62%
1 Month
-0.89%
3 Months
-16.97%
6 Months
-7.18%
1 Year
31.22%
2 Year
152.20%
Key data
Stock price
$15.51
DAY RANGE
$15.34 - $15.60
52 WEEK RANGE
$9.88 - $21.50
52 WEEK CHANGE
$35.87
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-28-2025
Company detail
CEO: Silviu Itescu
Region: US
Website: mesoblast.com
Employees: 80
IPO year: 2009
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: mesoblast.com
Employees: 80
IPO year: 2009
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Mesoblast Limited offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection. The company has strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd. and Grünenthal.
Recent news